These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24801386)

  • 1. A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats.
    Andreassen KV; Feigh M; Hjuler ST; Gydesen S; Henriksen JE; Beck-Nielsen H; Christiansen C; Karsdal MA; Henriksen K
    Am J Physiol Endocrinol Metab; 2014 Jul; 307(1):E24-33. PubMed ID: 24801386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog.
    Gydesen S; Andreassen KV; Hjuler ST; Hellgren LI; Karsdal MA; Henriksen K
    Am J Physiol Endocrinol Metab; 2017 Nov; 313(5):E598-E607. PubMed ID: 28292761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight.
    Gydesen S; Andreassen KV; Hjuler ST; Christensen JM; Karsdal MA; Henriksen K
    Am J Physiol Endocrinol Metab; 2016 May; 310(10):E821-7. PubMed ID: 26908506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The enduring metabolic improvement of combining dual amylin and calcitonin receptor agonist and semaglutide treatments in a rat model of obesity and diabetes.
    Larsen AT; Mohamed KE; Melander SA; Karsdal MA; Henriksen K
    Am J Physiol Endocrinol Metab; 2024 Aug; 327(2):E145-E154. PubMed ID: 38864815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administration.
    Hjuler ST; Andreassen KV; Gydesen S; Karsdal MA; Henriksen K
    Eur J Pharmacol; 2015 Sep; 762():229-38. PubMed ID: 26027795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference.
    Gydesen S; Hjuler ST; Freving Z; Andreassen KV; Sonne N; Hellgren LI; Karsdal MA; Henriksen K
    Br J Pharmacol; 2017 Apr; 174(7):591-602. PubMed ID: 28109166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Dual Amylin- and Calcitonin-Receptor Agonist KBP-042 Works as Adjunct to Metformin on Fasting Hyperglycemia and HbA1c in a Rat Model of Type 2 Diabetes.
    Hjuler ST; Gydesen S; Andreassen KV; Karsdal MA; Henriksen K
    J Pharmacol Exp Ther; 2017 Jul; 362(1):24-30. PubMed ID: 28438778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy.
    Larsen AT; Sonne N; Andreassen KV; Gehring K; Karsdal MA; Henriksen K
    J Pharmacol Exp Ther; 2019 Jul; 370(1):35-43. PubMed ID: 31028106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does receptor balance matter? - Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models.
    Larsen AT; Mohamed KE; Sonne N; Bredtoft E; Andersen F; Karsdal MA; Henriksen K
    Biomed Pharmacother; 2022 Dec; 156():113842. PubMed ID: 36242844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile.
    Larsen AT; Gydesen S; Sonne N; Karsdal MA; Henriksen K
    BMC Endocr Disord; 2021 Jan; 21(1):10. PubMed ID: 33413317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Dual Amylin and Calcitonin Receptor Agonist, KBP-066, Induces an Equally Potent Weight Loss Across a Broad Dose Range While Higher Doses May Further Improve Insulin Action.
    Sonne N; Larsen AT; Andreassen KV; Karsdal MA; Henriksen K
    J Pharmacol Exp Ther; 2020 Apr; 373(1):92-102. PubMed ID: 31992608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats.
    Andreassen KV; Larsen AT; Sonne N; Mohamed KE; Karsdal MA; Henriksen K
    Mol Metab; 2021 Nov; 53():101282. PubMed ID: 34214708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral salmon calcitonin enhances insulin action and glucose metabolism in diet-induced obese streptozotocin-diabetic rats.
    Feigh M; Hjuler ST; Andreassen KV; Gydesen S; Ottosen I; Henriksen JE; Beck-Nielsen H; Christiansen C; Karsdal MA; Henriksen K
    Eur J Pharmacol; 2014 Aug; 737():91-6. PubMed ID: 24858364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dual amylin- and calcitonin-receptor agonist KBP-042 increases insulin sensitivity and induces weight loss in rats with obesity.
    Hjuler ST; Gydesen S; Andreassen KV; Pedersen SL; Hellgren LI; Karsdal MA; Henriksen K
    Obesity (Silver Spring); 2016 Aug; 24(8):1712-22. PubMed ID: 27296301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Calcitonin Receptor Plays a Major Role in Glucose Regulation as a Function of Dual Amylin and Calcitonin Receptor Agonist Therapy.
    Larsen AT; Sonne N; Andreassen KV; Karsdal MA; Henriksen K
    J Pharmacol Exp Ther; 2020 Jul; 374(1):74-83. PubMed ID: 32317372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral salmon calcitonin attenuates hyperglycaemia and preserves pancreatic beta-cell area and function in Zucker diabetic fatty rats.
    Feigh M; Andreassen KV; Neutzsky-Wulff AV; Petersen ST; Hansen C; Bay-Jensen AC; Henriksen JE; Beck-Nielsen H; Christiansen C; Henriksen K; Karsdal MA
    Br J Pharmacol; 2012 Sep; 167(1):151-63. PubMed ID: 22506938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel oral form of salmon calcitonin improves glucose homeostasis and reduces body weight in diet-induced obese rats.
    Feigh M; Henriksen K; Andreassen KV; Hansen C; Henriksen JE; Beck-Nielsen H; Christiansen C; Karsdal MA
    Diabetes Obes Metab; 2011 Oct; 13(10):911-20. PubMed ID: 21615667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss.
    Thorsø Larsen A; Karsdal MA; Henriksen K
    Eur J Pharmacol; 2023 Sep; 954():175837. PubMed ID: 37329973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are insulin sensitizers the new strategy to treat Type 1 diabetes? A long-acting dual amylin and calcitonin receptor agonist improves insulin-mediated glycaemic control and controls body weight.
    Melander SA; Larsen AT; Karsdal MA; Henriksen K
    Br J Pharmacol; 2024 Jun; 181(12):1829-1842. PubMed ID: 38378168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss.
    Larsen AT; Melander SA; Sonne N; Bredtoft E; Al-Rubai M; Karsdal MA; Henriksen K
    Biomed Pharmacother; 2023 Aug; 164():114969. PubMed ID: 37269811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.